Drugs / ECC0509
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05012423 | Jul 2021 → Jul 2023 | metabolic dysfunction-associated steatohepatitis, osteoarthritis | Eccogene | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07288138 | Dec 2025 → Sep 2027 expected | metabolic dysfunction-associated steatohepatitis | Eccogene | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECC0509 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05012423 ↗ |
| Action | Inhibit | “an SSAO Inhibitor (ECC0509)” NCT07288138 ↗ |
| Route | Oral | “administered as oral capsules” NCT05012423 ↗ |